Ultra-High Performance Liquid Chromatography-Mass Spectrometry-based Serum Metabolomics for Early Diagnosis of Refractory Tumor-induced Osteomalacia: A Case-control Study
Authors' conclusion
We investigate the global metabolomes of refractory TIO and identify potential prognostic biomarkers preliminarily. A high sensitivity and specificity panel were identified as promising discriminating predictors, which need to be verified in more patients. This work may demonstrate novel insights into TIO prognosis and pathogenesis.
Study context
- Population
- Patients with tumor-induced osteomalacia (TIO) and matched controls; preoperative sera
- Participants
- 86 samples
- Comparison
- Refractory (nonremission) vs recovered TIO vs matched healthy controls, preoperative serum metabolomics
- TIO recoveryn = 32
- Nonremissionn = 11
- Controlsn = 43reference
- Outcome
- Panel of L-pipecolic acid + 2-dodecylbenzenesulfonic acid for TIO prognosis (random forest)
Methodological detailscross-sectional comparison of metabolomic profile between TIO and normal control, longitudinal study for prognostic model
- Cross-sectional comparison of metabolomic profile between TIO and normal control
- Longitudinal study for prognostic model
Main finding
As reported in the abstract
AUC of L-pipecolic acid + 2-dodecylbenzenesulfonic acid panel for TIO prognosis
0.921
95% CI 0.787–0.995
Observational data: associations, not effects.
Original publication
Ultra-High Performance Liquid Chromatography-Mass Spectrometry-based Serum Metabolomics for Early Diagnosis of Refractory Tumor-induced Osteomalacia: A Case-control Study. J Clin Endocrinol Metab. Published 31 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →